(Total Views: 577)
Posted On: 09/22/2025 2:43:13 AM
Post# of 157281
Re: Nt2innvovate #157138
Quote:
Ohm. Take a look at iOncologi when you get a chance. They are creating an mRNA shot that might also increase susceptibility to PD-1, ?"cold to hot" They are the ones CNBC recently profiled.
IOncologi's drug is called IONC301 which are stem cells that have increased CCR2 expression. The ligand at play here is CCL2 which has activities that mirror those of CCL5 (RANTES). They're basically backup systems of each other. The main difference in activity between their drug and leronlimab is that instead of blocking ligands the increased CCR2 gets activated by its ligands along with the accompanying inflammation and migration of tumor cells. Taking that into consideration I think leronlimab is the better drug.
Quote:
Are we maybe hoping the open label data will be so good we get conditional approval with these trials with phase 4 confirmation to follow?
On the primary trial it's doubtful. With the follow-up study data it's a possibility.
(8)
(0)
